NOX receives FY17 R&D Tax Rebate
Filed with ASX · · 3 pages · English
Earlier from Noxopharm
- EOY Guidance on 2018 NOX66 Clinical Development Strategy
- Nyrada Inc Opens Capital Raise - Memorandum Released
- NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
- Clarification of Incorrect Information
- Promising Interim Clinical Data for NOX66
Later from Noxopharm
- NOX closes $4m capital raising for US subsidiary Nyrada Inc
- Appendix 4D and Half Year Accounts
- NOX Reports NOX66 Clinical Data
- Evidence of Abscopal Responses in Patients
- NOX raises $10.8 M to advance clinical program
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm